Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Life Science Investing
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 Life Science Investing
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs Pharmaceutical Investing
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update Life Science Investing
Telescope Innovations Secures Third Self-Driving Lab Deployment with Major Global Pharmaceutical Company Life Science Investing
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy Life Science Investing
Bristol Myers Squibb Announces Opdivo® in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma Life Science Investing
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer Pharmaceutical Investing
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer Pharmaceutical Investing
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia Pharmaceutical Investing
